Healthcare Economics & Policy

The healthcare sector has been on fire over the last several years, with investors in the space seeing big returns on stocks. Even during periods of volatility across the stock market at the end of 2018, the healthcare sector remained consistent, with “stellar returns,” Bloomberg reported.

Emergency department (ED) visits for people with at least one of six prevalent chronic conditions contributed to approximately 50 percent of all annual visits at nearly 750 hospitals in 2017. 

A bigger bonus size for physicians is associated with higher-value medicine, according to a recent study published in JAMA Open Network.

Surprise medical bills, where patients get a sky-high bill in the mail weeks after they received care, are a major issue for consumers. But one state that has tried to help alleviate the pain of the bills has been overwhelmed.

CMS’ newly proposed interoperability rules are a part of a broader effort to empower patients by ensuring they have access to their medical records, CMS Administrator Seema Verma said during the HIMSS conference in Orlando on Feb. 12.

Healthcare spending per person rose to an all-time high in 2017 for those covered by employer-sponsored insurance, according to the Health Care Cost Institute (HCCI). Average healthcare spending per individual rose 4.2 percent to $5,641, including medical and pharmacy claims.

Health insurance is big business, according to revenue reports from major players in the space. In fact, the five largest conglomerates in healthcare and pharmaceuticals are on track to outpace revenues of the five preeminent technology companies, according to Axios.

Medicare and Medicaid prices have grown at a slower pace than the private market, according to an analysis from the Urban Institute.

Oregon lawmakers are “taking another pass” at universal healthcare for the residents of state, according to a new report by The Register Guard. If SB 770 is passed, it will create a committee that would “design, implement and run a state health insurance plan.” 

Johnson & Johnson (J&J) will provide the list price of its prescription drugs in television advertisements starting in late March. The company will be the first manufacturer to take such a step, according to The New York Times.

Women are less successful at receiving funds for research if the application reviewer is asked to evaluate the principal investigator, rather than the quality of the science, according to research published in The Lancet.

The price for a drug that treats Lambert-Eaton Myasthenic Syndrome (LEMS), a rare neuromuscular disorder that impacts strength and impairs walking, went from cost-free to the price of a house—$375,000 to be exact.